EUVIMEDEUVIMED entdecken
Kommentar

In thrombotic antiphospholipid syndrome, DOACs vs. VKAs increase arterial thrombotic events but not major bleeding

Efstratios Koutroumpakis, Anita Deswal

Annals of Internal Medicine · 2023

DOI: 10.7326/j23-0016 ↗

Kurz gefasst

Kommentar in der Zeitschrift Annals of Internal Medicine, 2023. Verfasst von Efstratios Koutroumpakis und 1 weiteren Autor:innen. Beteiligte Einrichtung: University of Texas MD Anderson Cancer Center, Houston, Texas, USA (E.K., A.D.). Hauptthemen laut MEDLINE: Antiphospholipid Syndrome, Thrombosis. Die Arbeit wurde bisher 1-mal zitiert (Crossref).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antiphospholipid SyndromeThrombosisHumansAdministration, OralAnticoagulantsHemorrhageVitamin KMeta-Analysis as Topic

Substanzen

AnticoagulantsVitamin K

Autor:innen und Institutionen

  • University of Texas MD Anderson Cancer Center, Houston, Texas, USA (E.K., A.D.).

Zitieren

APA

Koutroumpakis, E., & Deswal, A. (2023). In thrombotic antiphospholipid syndrome, DOACs vs. VKAs increase arterial thrombotic events but not major bleeding. Annals of Internal Medicine. https://doi.org/10.7326/j23-0016

Vancouver

Koutroumpakis E, Deswal A. In thrombotic antiphospholipid syndrome, DOACs vs. VKAs increase arterial thrombotic events but not major bleeding. Annals of Internal Medicine. 2023. doi:10.7326/j23-0016

BibTeX
@article{Koutroumpakis2023,
  author = {Koutroumpakis, Efstratios and Deswal, Anita},
  title = {In thrombotic antiphospholipid syndrome, DOACs vs. VKAs increase arterial thrombotic events but not major bleeding},
  journal = {Annals of Internal Medicine},
  year = {2023},
  doi = {10.7326/j23-0016}
}
Kostenlos starten →